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Abstract
Introduction Polyamines affect proliferation, differentiation,
migration and apoptosis of cells, indicating their potential as a
target for cancer chemotherapy. Ornithine decarboxylase
converts ornithine to putrescine and is the rate-limiting step in
polyamine synthesis.
α -Difluoromethylornithine (DFMO) irreversibly inhibits ornithine
decarboxylase and MDA-MB-435 human breast cancer
metastasis to the lung without blocking orthotopic tumor
growth. This study tested the effects of DFMO on orthotopic
tumor growth and lung colonization of another breast cancer cell
line (MDA-MB-231) and the effects on bone metastasis of MDA-
MB-435 cells.
Methods MDA-MB-231 cells were injected into the mammary
fat pad of athymic mice. DFMO treatment (2% per orally) began
at the day of tumor cell injection or 21 days post injection. Tumor
growth was measured weekly. MDA-MB-231 cells were
injected into the tail vein of athymic mice. DFMO treatment
began 7 days prior to injection, or 7 or 14 days post injection.
The number and incidence of lung metastases were determined.
Green fluorescent protein-tagged MDA-MB-435 cells were
injected into the left cardiac ventricle in order to assess the
incidence and extent of metastasis to the femur. DFMO
treatment began 7 days prior to injection.
Results DFMO treatment delayed MDA-MB-231 orthotopic
tumor growth to a greater extent than growth of MDA-MB-435
tumors. The most substantial effect on lung colonization by
MDA-MB-231 cells occurred when DFMO treatment began 7
days before intravenous injection of tumor cells (incidence
decreased 28% and number of metastases per lung decreased
35–40%). When DFMO treatment began 7 days post injection,
the incidence and number of metastases decreased less than
10%. Surprisingly, treatment initiated 14 days after tumor cell
inoculation resulted in a nearly 50% reduction in the number of
lung metastases without diminishing the incidence. After
intracardiac injection, DFMO treatment decreased the
incidence of bone metastases (55% vs 87%) and the area
occupied by the tumor (1.66 mm2 vs 4.51 mm2, P < 0.05).
Conclusion Taken together, these data demonstrate that
DFMO exerts an anti-metastatic effect in more than one
hormone-independent breast cancer, for which no standard
form of biologically-based treatment exists. Importantly, the data
show that DFMO is effective against metastasis to multiple sites
and that treatment is generally more effective when
administered early.
BSA = bovine serum albumin; DFMO = α -difluoromethylornithine; DMEM = Dubecco's modified Eagle's medium; GFP = green fluorescent protein; 
HBSS = Hanks Balanced Salt Solution; ODC = ornithine decarboxylase; PBS = phosphate-buffered saline; RT-PCR = reverse transcriptase-polymer-
ase chain reaction; TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labeling.Breast Cancer Research    Vol 7 No 5    Richert et al.
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Introduction
Metastasis is the leading cause of death of breast cancer
patients. As tumors progress from hormone-dependent to hor-
mone-independent, their risk of metastasis increases and the
treatment options decrease. There are currently no efficacious
biologically-based therapies for the more aggressive hormone-
independent breast cancers. It is therefore important to
explore potential therapies that may be effective against both
metastasis and growth of hormone-independent breast
tumors.
Polyamines are organic compounds derived from decarboxyla-
tion of the amino acid ornithine. These compounds play a role
in a wide variety of cellular functions including proliferation, dif-
ferentiation, migration and apoptosis [1]. They are required for
cell viability, as demonstrated by the lethality of ornithine
decarboxylase (ODC) null mutations in mice [2]. ODC is the
rate-limiting enzyme in polyamine synthesis: It converts orni-
thine to putrescine to begin the polyamine cascade. Overex-
pression of ODC in the immortalized, but non-tumorigenic,
mammary epithelial cell line MCF10A results in a partially
transformed phenotype as well as in the activation of ERK,
which is often activated in breast cancers [3,4]. Previous stud-
ies demonstrated that increased ODC activity correlates with
transition to hormone independence, increased anaplasia and
metastasis. Increased ODC activity is an independent adverse
prognostic factor for overall breast cancer survival in women
with localized disease [5-7], suggesting that increased activity
of the polyamine pathway may result in more aggressive, hor-
mone-independent breast cancers.
α -Difluromethylornithine (DFMO) is an irreversible inhibitor of
ODC. Treatment with DFMO results in decreased polyamine
pools causing a cytostatic effect. Our laboratory previously
demonstrated that DFMO treatment decreased lung metasta-
sis from the estrogen receptor-negative/progesterone recep-
tor-negative breast carcinoma cell line MDA-MB-435
xenografts, while having only a modest or absent effect on the
growth of the orthotopic tumors [8,9]. Previous studies have
shown that DFMO (0.5–3% in drinking water) was well toler-
ated in both rats and mice. The minimal toxicities of DFMO
make it a suitable candidate for long-term treatments.
The studies described here were designed to address two
questions. First, does DFMO reduce metastasis to sites other
than lung? To address this question, we took advantage of a
recently developed enhanced green fluorescent protein
(GFP)-expressing variant of MDA-MB-435 [10,11]. Second,
does DFMO affect orthotopic tumor growth and metastasis of
another hormone-independent breast carcinoma? To test this
question, we utilized the estrogen receptor-negative/proges-
terone receptor-negative MDA-MB-231 cell line. We present
here that DFMO can decrease metastasis of MDA-MB-435
cells to the bone and can affect lung metastasis and ortho-
topic tumor growth of MDA-MB-231 cells.
Materials and methods
Cell lines
MDA-MB-231 and MDA-MB-435 human breast cancer cell
lines were kindly provided by Dr Janet E Price at the University
of Texas MD Anderson Cancer Center. They were cultured in
DMEM/Ham's F12 medium supplemented with 5% fetal
bovine serum, 1% non-essential amino acids, 1 mM sodium
pyruvate, and were maintained at 37°C with 5% CO2 in a
humidified atmosphere. The cells were passaged using
0.125% trypsin, 2 mM ethylenediamine tetraacetic acid in
Ca2+/Mg2+-free Dulbecco's PBS.
Metastasis assays
All animals were maintained under the guidelines of the
IACUC of the University of Alabama at Birmingham under reg-
istered protocols. Female athymic mice (Harlan Sprague-Daw-
ley, Inc., Indianapolis, IN, USA) were used for all studies.
To study bone metastasis, 4-week-old to 6-week-old female
mice were injected intracardially with 3 × 105 GFP-labeled
MDA-MB-435 cells in 0.2 ml ice-cold Hanks Balanced Salt
Solution (HBSS). Seven days prior to injection, two groups of
10 mice each were randomly selected. One group remained
untreated, while the second group was provided DFMO as a
2% solution in the drinking water ad libitum until 6 weeks post
injection. This dose had been previously demonstrated as effi-
cacious. The mice were euthanized and the femurs dissected
away from the soft tissue. Bone metastases were visualized by
fluorescence microscopy [10,11]. Brightfield and fluorescent
photographs were analyzed using Sigma Scan (SPSS Inc.,
Chicago, IL, USA) to determine the total area of bone, the area
of bone occupied by fluorescing tumor cells and the percent-
age of bone occupied by fluorescing tumor cells.
MDA-MB-231 breast cancer cells (2 × 105 cells in 0.2 ml
HBSS) were injected intravenously into the lateral tail vein of
3-week-old to 4-week-old athymic mice to evaluate lung colo-
nization as metastases from an orthotopically growing tumor
are relatively rare from this cell line. Each treatment group con-
sisted of 20 mice. DFMO treatment (2% in drinking water) was
administered using three schedules beginning: 7 days prior to
tumor cell injection, 7 days after tumor cell injection, or 14
days after tumor cell injection. DFMO was administered until
the experiment was terminated (4–6 weeks post injection).
Control animals did not receive DFMO. At termination, the
lungs were removed and fixed in Bouin's fixative diluted 1:5
with neutral-buffered formalin. The number of lungs with sur-
face metastases were determined, as well as the number of
surface metastases per lung by examination under a dissect-
ing microscope, as described elsewhere [12].
Orthotopic tumor growth was measured by injecting MDA-
MB-231 breast cancer cells (5 × 105 cells in 0.1 ml HBSS)
into the second thoracic mammary fat pad of 5-week-old to 6-
week-old female athymic nude mice, as described previouslyAvailable online http://breast-cancer-research.com/content/7/5/R819
R821
[12]. DFMO treatment (2% in drinking water) began at the
time of mammary fat pad injection or at 21 days post injection.
The control group consisted of 17 mice, the group started on
DFMO at the time of injection consisted of 20 mice, while
three mice began treatment 21 days post injection. Tumor
growth was monitored weekly by measuring the tumor length
and width with a caliper and was reported as the mean tumor
diameter as previously described [12]. Since DFMO retarded
tumor growth, DFMO-treated mice were euthanized when
average local tumor diameters reached approximately 1.5 cm.
In a subsequent experiment, all animals were euthanized 6
weeks post tumor cell injection. To examine growth parame-
ters, mice were injected with 100 mg/kg BrdU approximately
2 hours prior to euthanasia. Tumors were removed and divided
into two portions. One aliquot was fixed in 10% neutral-buff-
ered formalin and processed for histological analysis. The
other aliquot was frozen in liquid nitrogen and stored at -70°C
for analysis of polyamine levels as described [9,13].
Polyamine levels
Athymic mice were injected subcutaneously (or in the mam-
mary fat pad as already described) with 5 × 105 MDA-MB-231
cells in 0.1 ml HBSS. The comparison of orthotopic sites with
ectopic sites was carried out in order to evaluate potential
pharmacologic differences. The mice were separated into two
animals per group. The control group was left untreated, while
DFMO treatment began 7 days prior to tumor cell injection, on
the day of injection, or 21 days post tumor cell injection. At 6
weeks post injection, tumors were removed and homogenized
in 25 mM Tris-HCl buffer, pH 7.4, containing 0.1 mM ethylen-
ediamine tetraacetic acid and 2.5 mM dithiothreitol. The
homogenates were centrifuged for 30 min at 20,000 × g. An
aliquot of the supernatant was used to measure ODC activity.
The remaining aliquot was extracted with 0.6 N perchloric acid
for 1 hour at 4°C prior to centrifugation at 15,000 × g for 15
min. The supernatant was used for polyamine determination.
Polyamine levels were determined using high-pressure liquid
chromatography as previously described [9,13].
Quantification of bromodeoxyuridine incorporation
Incorporation of BrdU was determined using immunohisto-
chemical staining. Briefly, the sections were deparaffinized
using xylenes and ethanol, and were then treated with 3%
hydrogen peroxide for 10 min, 0.1% trypsin for 30 min and 2
N HCl for 30 min with PBS washes between each treatment.
The sections were blocked with 5% normal goat serum in 1%
BSA, 0.05% Tween 20 and 0.1% NaN3 in PBS followed by a
2-hour incubation at 37°C in a 1:1000 dilution of a monoclonal
anti-BrdU antibody (B2531; Sigma, St. Louis, MO, USA). The
sections were rinsed and then incubated for 1 hour at 37°C in
a 1:5000 dilution of anti-mouse AlexaFluor Green. After the
final washes, the sections were cover-slipped in Vectashield
mounting media containing DAPI diluted 1:7 with non-DAPI-
containing Vectashield mounting media. Five photographs
(100 × magnification) from two sections of each tumor were
counted for BrdU-labeled cells and the total number of labeled
cells was graphed.
Quantification of TUNEL staining
Apoptotic cells were identified using the Apoptag plus stain-
ing kit from Chemicon (S7101; Temecula, CA, USA) accord-
ing to the manufacturer's instructions. Five photographs (63 ×
magnification) from two sections of each tumor were counted
for TUNEL-labeled cells, and the total number of labeled cells
was graphed.
Semi-quantitative RT-PCR
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA,
USA) and 500 ng was used for RT-PCR with a SuperscriptIII/
Platinum Taq One Step Kit (Invitrogen) as directed. Human
glyceraldehyde-3-phosphate dehydrogenase primers (5'-
GTGAAGGTCGGAGTCAACGGATT-3' and 5'-AGTGAT-
GGCATGGACTGTGGTC-3') and hypoxanthine phosphori-
bosyl transferase primers (5'-
CCAAAGATGGTCAAGGTCGC-3' and 5'-CTGCT-
GACAAAGATTCACTGG-3') were used to assess equal tem-
plate loadings, and the linear range for each primer pair was
determined independently. Human meprin α  levels were deter-
mined with the following primers: 5'-ATCGGAGGCACG-
GCTGGCGTG-3' and 5'-
GCCTGCCCTCATGGAGCTTACAG-3'. RT-PCR products
were separated on a 1% TAE/agarose gel and quantified
using a Stratagene Eagle Eye system with multiple
integrations.
Statistics
Comparisons between treatment groups and control-treated
mice were made using SigmaStat statistical software (SPSS
Inc.). For multiple group comparisons, one-way analysis of var-
iance was performed, followed by the Student-Neumann-
Keuls post-test. Results were considered statistically different
if P < 0.05.
Results and discussion
In normal tissues, ODC activity is increased by a variety of
environmental and genetic factors associated with carcino-
genesis, including ultraviolet light, asbestos and androgens.
Increased ODC activity persists in and is associated with a
wide variety of epithelial neoplasms including breast, skin,
colon and prostate (reviewed in [1]). Together, these correla-
tions suggest a role for ODC in tumor development and pro-
gression. Functional evidence supports this conclusion. In skin
carcinogenesis models, ODC heterozygous knockout mice
have significantly reduced tumor development [14].
Hormone-independent breast cancers are generally more
aggressive and metastatic than hormone-responsive tumors.
Unfortunately, there are currently no efficacious biologically-
based treatments for these more aggressive forms of breast
cancer whose survival rates are less than 26%. PolyaminesBreast Cancer Research    Vol 7 No 5    Richert et al.
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and ODC are increased in breast cancer compared with nor-
mal breast tissue, and increased ODC activity directly corre-
lates with a less differentiated and more metastatic tumor
phenotype [5,6,15]. ODC activity is also an independent
adverse prognostic factor for overall breast cancer survival
[5,6,15]. DFMO, an irreversible inhibitor of ODC, reduces
polyamine pools resulting in a cytostatic effect. Our previous
studies demonstrated that treatment with DFMO reduces lung
metastasis of the hormone-independent MDA-MB-435 breast
cancer cell line with only a modest effect on the growth of
orthotopic tumors [8,16]. This led to two questions: Can inhi-
bition of ODC activity by DFMO decrease metastasis of MDA-
MB-435 cells to another secondary site, namely bone? Can
DFMO decrease orthotopic tumor growth and lung metastasis
of another hormone-independent breast cancer cell line, MDA-
MB-231? DFMO inhibition of tumor growth and metastasis of
hormone-independent cells would strongly support targeting
the polyamine pathway as a potential treatment.
Polyamine levels are decreased in tumors treated with 
DFMO
Polyamine levels were determined in orthotopically (mammary
fat pad) and ectopically (subcutaneous) growing tumors in
order to demonstrate that DFMO was inhibiting ODC activity.
DFMO treatment beginning at either 7 days prior to injection
(d-7), on the day of injection (d0) or 21 days following (d+21)
injection of MDA-MB-231 cells into the mammary fat pad
resulted in decreased putrescine and spermidine levels with
only slight effects on spermine levels (Fig. 1). Putrescine levels
decreased from an average of 0.200 nmol/mg tissue in the
control samples to below the detection level in all of the
DFMO-treated samples, while the spermidine levels
decreased from a mean of 3.7905 nmol/mg in the untreated
samples to 1.606 nmol/mg after treatment. As expected
[17,18], the spermine levels decreased only slightly from an
average of 2.931 nmol/mg in the untreated controls to 2.390
nmol/mg after treatment. This demonstrates that ODC was
effectively inhibited by DFMO treatment.
Curiously, polyamine levels in MDA-MB-231 cells were signif-
icantly different when the cells were grown orthotopically ver-
sus those grown ectopically (Fig. 1). This result suggested
that DFMO treatments might exert different effects on cells
depending upon their location. The result is not entirely sur-
prising since several previous experiments have shown that
the biologic behavior of tumor cells can vary widely based
upon the site of injection [12].
DFMO treatment decreases bone metastasis by MDA-
MB-435 cells
We previously showed that MDA-MB-435 metastasis was
decreased by 74% to the lung when mice were treated with
DFMO [9] despite no apparent change in local tumor invasion.
That result indicated that DFMO was affecting the later stages
of metastasis (i.e. colonization). Breast cancers commonly
metastasize to bone [19]. While bone metastases are not
directly responsible for most breast cancer deaths, they result
in profoundly decreased quality of life. While current therapies
exist to decrease osteolysis and reduce sequella of bone
metastases, there are few options to diminish bone tumor bur-
den [19,20].
Taking into account the importance of breast cancer metasta-
sis to bone and observations that polyamine levels varied
depending upon tumor cell location in the body, we therefore
asked whether DFMO had an effect on bone metastasis. To do
this, we employed a model recently developed by ourselves
using GFP-labeled MDA-MB-435 cells [10,11]. This model
allows for relatively rapid assessment of the tumor burden in
bone and is not dependent solely upon radiographic imaging
and histology, which are less sensitive and more laborious,
respectively.
As for all xenograft models, metastases in bone are not
observed following orthotopic injection; tumor cells are there-
fore injected directly into the left ventricle of the heart. While
metastases develop in other bones, this study involved com-
plete analysis only on femurs because this site reflects
changes elsewhere [10,11] and because it is a site commonly
affected in women with breast cancer. DFMO treatment was
begun 7 days prior to intracardiac injection of GFP-labeled
MDA-MB-435 cells and lasted for the duration of the experi-
ment. Mice with fluorescently-labeled femoral tumors were
Figure 1
α -Difluoromethylornithine (DFMO) (2% per orally in drinking water)  decreases polyamine levels in mammary fat pad tumors of MDA-MB- 231 cells α -Difluoromethylornithine (DFMO) (2% per orally in drinking water) 
decreases polyamine levels in mammary fat pad tumors of MDA-MB-
231 cells. Polyamine levels were determined in control subcutaneous 
(s.c.) and mammary fat pad (mfp) tumors as well as in DFMO-treated 
tumors grown in the mammary fat pad. DFMO treatment began at either 
7 days prior to tumor cell injections (DFMO-7), on the day of injection 
(DFMO 0) or 21 days post injection (DFMO+21). Putrescine (black), 
spermidine (diagonal line) and spermine (cross-hatched) levels are 
graphed as nanomoles per milligram of tumor.Available online http://breast-cancer-research.com/content/7/5/R819
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counted (Fig. 2a,b). DFMO treatment decreased the number
of mice with bone metastases from 87.5% to 55.5% (Fig.
2a,b). The GFP label in each femur was then quantified by
image analysis and the area of bone occupied by tumor cells
was calculated (Fig. 2c,d). DFMO significantly decreased the
area of bone occupied by the tumor from 4.51 to 1.69 mm2
(Fig. 2c; P < 0.05) and the percentage of bone occupied by
the tumor decreased from 19.03% to 6.45% (Fig. 2d; P <
0.05). The intensity of fluorescence was not a variable for
these analyses since we previously observed that intensity
was dependent upon the depth of tumor cells to the bone sur-
face [10]. As an internal control, however, bones were exam-
ined from both sides, and the areas occupied by tumor were
found to be comparable (data not shown). Previous and ongo-
ing independent studies have validated tumor location by his-
tology and histomorphometry.
To the best of our knowledge, these are the first data to dem-
onstrate efficacy of DFMO for metastases at a site other than
the lung. The polyamine pathway therefore shows promise as
a target for decreasing metastasis to multiple sites in breast
cancer patients. Our studies have a modest limitation in that
they only test efficacy of DFMO against the MDA-MB-435
cells to bone. We and other workers [21-23] have shown that
the MDA-MB-231 cells will also colonize bone. But in the
absence of GFP-tagged variants, the MDA-MB-231 bone
metastasis assays are limited to radiologic or histologic detec-
tion methods that are less sensitive or more laborious. They
were therefore not utilized here.
MDA-MB-231 orthotopic tumor growth is delayed by 
DFMO
This study, combined with previous data, indicates that the
polyamine pathway can be modulated to affect primary tumor
growth and metastasis of a hormone-independent breast can-
cer cell line (MDA-MB-435). To begin assessing whether
DFMO treatment might be generally efficacious against other
hormone-independent breast cancers, we examined ortho-
topic tumor growth and lung colonization of a second meta-
static hormone-independent breast cancer cell line, MDA-MB-
231.
Orthotopic tumor growth of MDA-MB-435 cells was previ-
ously shown to be mildly, but significantly, delayed by or not
Figure 2
α -Difluoromethylornithine (DFMO) decreases the incidence and size of bone metastases from MDA-MB-435 cells α -Difluoromethylornithine (DFMO) decreases the incidence and size of bone metastases from MDA-MB-435 cells. Green fluorescent protein-
labeled MDA-MB-435 cells were injected intracardially into athymic mice. DFMO (2% per orally in drinking water ad libitum) treatment began 7 days 
prior to injection and continued for 6 weeks post injection. Bone metastases were visualized using a fluorescence microscope. (a) Photographs of 
femurs from control (n = 10) and DFMO-treated (n = 10) mice show the presence and size of the bone metastases. (b) Incidence of metastasis was 
determined by counting the number of mice with green fluorescence in the femur regardless of size of the mass. Image analysis was used to quantify 
fluorescence in each bone. (c) The area of tumor in bone was quantified by comparing the total area of the femur with the area containing green flu-
orescence. (d) The percentage of bone occupied by the tumor was also determined.Breast Cancer Research    Vol 7 No 5    Richert et al.
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affected by treatment with DFMO [8,9]. Untreated MDA-MB-
435 tumors reached a size of 100 mm2 2 weeks earlier than
DFMO-treated tumors. We had also previously shown that
MDA-MB-231 orthotopic tumors were delayed by DFMO
treatment. We repeated this experiment with slight variations.
DFMO treatment began either on the day of injection (d0) or
21 days post injection (d+21) of MDA-MB-231 cells into the
second thoracic mammary fat pad and were continued until
tumors reached a mean tumor diameter of approximately 1.2
cm (Experiment 1) or until 6 weeks post injection (Experiment
2). DFMO treatment delayed orthotopic tumor growth to ~1.2
cm from 42 days in control animals to 77 days (Fig. 3). At 42
days post injection, control tumors were 1.15 cm while
DFMO-treated tumors were 0.75 cm when treatment began
concurrent with tumor injection, and surprisingly smaller (0.62
cm) when treatment began on day 21 (Fig. 3).
DFMO treatment can thus delay orthotopic tumor growth of
more than one breast cancer cell line, albeit with heterogene-
ous responses. MDA-MB-231 cells were more sensitive to
DFMO at the primary site; that is, MDA-MB-435 tumors were
mildly delayed (~2 weeks) or not delayed at all compared with
a delay of ~5 weeks for MDA-MB-231. Postponement of
DFMO treatment until 3 weeks post injection also inhibited
MDA-MB-231 tumor growth, suggesting that DFMO could still
be efficacious if administered at the time of diagnosis.
MDA-MB-231 lung metastasis is decreased by DFMO
Like MDA-MB-435 cells, DFMO reduced lung metastasis of
MDA-MB-231 cells. The latter, however, had to be evaluated
following injection of cells directly into the lateral tail vein
because the parental cells are not effective at spontaneous
metastasis. This experimental design afforded examination of
scheduling since all tumor cells were administered as a bolus.
While lung metastasis was reduced in all treatment groups, we
were surprised by the pattern of suppression, even though it
was reproducible. The incidence of metastases (i.e. proportion
of mice developing lung metastases) decreased as expected.
Earlier treatment resulted in fewer mice with metastases: 25%,
10% and 0% decreased for treatments beginning d-7, d0 and
d+14 (Fig. 4a). However, the mice receiving DFMO beginning
on d+14 showed diminishment of the number of metastases
per lung (42%, mean = 12.5/lung vs 22.2/lung for controls),
compared with no effect for d+7 (mean = 20.5/lung) and 32%
for d-7 (mean = 15.1/lung) treatment schedules (Fig. 4b).
Despite the trend toward decreased lung metastasis, and in
contrast to MDA-MB-435 cells, the reductions in lung metas-
tasis never reached statistical significance (P  < 0.05) for
MDA-MB-231 cells. Nonetheless, DFMO was clearly exerting
reproducible effects on breast carcinoma growth in the mam-
mary fat pad and in the lung.
DFMO treatment decreases proliferation in MDA-MB-
231 orthotopic tumors
To begin addressing mechanisms for increased susceptibility
of MDA-MB-435 cells to spontaneous metastasis suppression
and of MDA-MB-231 cells to suppression of tumor growth, we
performed additional studies. In vitro growth was not signifi-
cantly affected (data not shown). To further assess growth and
apoptosis, we examined MDA-MB-231 tumors growing ortho-
topically by BrdU and TUNEL staining to determine whether
DFMO treatment altered proliferation or apoptosis, respec-
tively. We found that DFMO treatment beginning d0 increased
apoptosis (Fig. 5a) and slightly decreased proliferation (Fig.
5b) compared with control tumors. The decrease in BrdU labe-
ling is consistent with, but less dramatic than, the 60%
decrease of Ki67 labeling observed in DFMO-treated MDA-
MB-435 tumors, while the increase in TUNEL staining is in
contrast to the MDA-MB-435 tumors where no change in
apoptosis was observed, even though cleaved caspase-3 lev-
els were increased fourfold. Non-apoptotic necrosis was
decreased by 60% in the MDA-MB-435 tumors, resulting in
no change in overall tumor volume [24].
Meprin α  expression is affected by DFMO in MDA-MB-
435 cells
Since we previously showed that DFMO does not affect local
tumor invasion of either MDA-MB-231 or MDA-MB-435 cells,
we reasoned that DFMO was exerting its major effect on later
stages of metastasis. This conclusion incorrectly led us to
hypothesize that proteinases were not (or only modestly)
affected by DFMO treatment. However, recent evidence
Figure 3
α -Difluoromethylornithine (DFMO) delays orthotopic tumor growth of  MDA-MB-231 cells α -Difluoromethylornithine (DFMO) delays orthotopic tumor growth of 
MDA-MB-231 cells. Athymic mice were injected into the second tho-
racic mammary fat pad with MDA-MB-231 cells. DFMO treatment (2% 
per orally) began either contemporaneously (▲ , n = 20) or 21 days 
post injection (▼ , n = 3). Mammary fat pad tumor length and width were 
measured once weekly. Control (● , n = 17) and 21 days post injection 
(DFMO+21) animals were sacrificed 6 weeks post injection. Day of 
injection (DFMO 0) animals were euthanized either 6 weeks (n = 10) or 
11 weeks (n = 10) post injection.Available online http://breast-cancer-research.com/content/7/5/R819
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suggested that proteinases, and their corresponding inhibi-
tors, have roles in tumor progression at steps other than inva-
sion [25], prompting a closer look.
Meprin α  is a zinc-dependent endopeptidase that is normally
expressed in kidney and intestinal epithelial cells. It is found as
either an apical membrane-bound form or as a secreted pro-
tein. At different stages of development, meprin α  is expressed
in a variety of tissues. In vitro, matrix proteins such as fibronec-
tin, laminin and collagen are meprin α  substrates. In some epi-
thelial carcinomas, meprin α  secretion can occur both apically
and basolaterally, and is activated by plasmin released by stro-
mal fibroblasts. Together these data indicate that meprin α  can
contribute to cancer invasion and/or metastasis.
To assess the impact of DFMO treatment on meprin α , MDA-
MB-435 and MDA-MB-231 cells were treated in vitro with 1
mM DFMO ± 2.5 mM putrescine (to demonstrate that the inhi-
bition is specific for ODC) for 48 hours. Semi-quantitative RT-
PCR showed that DFMO treatment had no effect on meprin α
expression in MDA-MB-231 cells, while meprin α  expression
was decreased by greater than 50% in MDA-MB-435 cells
(Fig. 6). Administration of putrescine partially reversed the
effect of DFMO in MDA-MB-435 cells (Fig. 6b,d). Although
not an exhaustive study, the meprin α  results highlight the
heterogeneity between different hormone-independent breast
carcinomas with regard to their response to DFMO.
While there are likely to be other mechanisms involved, the dif-
ference in meprin α  levels in DFMO-treated MDA-MB-231 and
MDA-MB-435 cells provides at least a partial explanation for
Figure 4
α -Difluoromethylornithine (DFMO) treatment decreases lung metastasis  of MDA-MB-231 cells α -Difluoromethylornithine (DFMO) treatment decreases lung metastasis 
of MDA-MB-231 cells. MDA-MB-231 cells were injected into the tail 
vein of athymic mice. DFMO treatment (2% per orally) began either 7 
days prior to (DFMO-7), or 7 days (DFMO+7) or 14 days (DMFO+14) 
after, tumor cell injection. Mice were killed either 4 weeks (Experiment 
1) or 6 weeks post injection (Experiment 2). Lungs were removed and 
fixed in Bouin's fixative diluted 1:5 in neutral buffered formalin. Each 
lung was examined for the presence of surface metastases. (a) The 
incidence of mice with lung metastases was graphed as a percentage 
of the total number of mice (n = 10 for each group). (b) The average 
number of metastases per lung was graphed as a percentage of the 
control (n = 10 for each group). Experiment 1 (black) and Experiment 2 
(small hatched) are graphed separately as well as combined (large 
hatched).
Figure 5
α -Difluoromethylornithine (DFMO) treatment affects both cell prolifera- tion and cell death in MDA-MB-231 orthotopic tumors α -Difluoromethylornithine (DFMO) treatment affects both cell prolifera-
tion and cell death in MDA-MB-231 orthotopic tumors. (a) TUNEL anal-
ysis and (b) BrdU analysis of MDA-MB-231 orthotopic tumors from 
either control mice or mice treated with 2% DFMO in the drinking water 
beginning at the day of injection.Breast Cancer Research    Vol 7 No 5    Richert et al.
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the different metastatic phenotypes of these cells in response
to DFMO.
In support of our data, another inhibitor of polyamine pathway
activity, SL11144, inhibited the growth of both MDA-MB-231
and MDA-MB-435 cells in vitro and of MDA-MB-231 ortho-
topic tumor growth in vivo [26]. In vitro cell death assays dem-
onstrated a differential effect of SL11144 inhibition on the
time line of apoptosis. Specifically, MDA-MB-435 cells exhib-
ited significant DNA laddering at 12 hours after treatment,
while MDA-MB-231 cells only showed the initial stages of lad-
dering at 96 hours post-treatment. These results were
explained by more potent activation of caspases and rapid
cytochrome c release in MDA-MB-435 cells in response to the
inhibitor compared with MDA-MB-231 cells. Similar to the
studies reported here, SL11144 was effective against both
cell lines, but the effect was different between the two lines.
Although heterogeneous responses were observed in the cell
lines examined in the present study, the results highlight the
potential utility of DFMO for the treatment of advanced hor-
mone-independent breast cancers. Moreover, the finding that
DFMO can significantly reduce bone metastasis warrants fur-
ther studies into the utilization of polyamine pathway modula-
tors in combination with other therapies for control of cancer
metastasis.
Conclusion
DFMO, a potent inhibitor of polyamine metabolism, blocks pri-
mary tumor growth and/or metastasis to the lung and bone
from hormone-independent breast carcinoma xenografts.
While the effects are heterogeneous, the findings warrant fol-
low-up into the utilization of polyamine pathway modulators in
combination with other therapies for control of this particularly
difficult-to-treat class of breast carcinomas.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MMR provided Figs 1, 3, 4 and 5, and drafted the manuscript.
PAP and DJD provided Fig. 2. GM and JSB helped conceive
of the meprin part of the study and provided Fig. 6. SW
assisted with multiple technical aspects of this study. LMD
performed the high-pressure liquid chromatography to deter-
mine polyamine levels. AM, MMR and DRW conceived of the
study and helped to draft the manuscript. All authors have read
and approved the final version of this manuscript.
Figure 6
In vitro α -difluoromethylornithine (DFMO) treatment decreases meprin α  expression in MDA-MB-435 cells, but not in MDA-MB-231 cells In vitro α -difluoromethylornithine (DFMO) treatment decreases meprin α  expression in MDA-MB-435 cells, but not in MDA-MB-231 cells. End-point 
RT-PCR analysis of total RNA from (a) MDA-MB-231 cells or (b) MDA-MB-435 cells, either left untreated (C), treated with 1 mM DFMO for 48 
hours (D) or treated with 1 mM DFMO plus 2.5 mM putrescine for 48 hours (D + P). Quantities of meprin α  mRNA in (c) MDA-MB-231 cells or (d) 
MDA-MB-435 cells were normalized to glyceraldehyde-3-phosphate dehydrogenase levels (GADPH) – normalization to hypoxanthine phosphoribo-
syl transferase [HPRT] was also performed in (a). Meprin α  expression levels are graphed as a percentage of control.Available online http://breast-cancer-research.com/content/7/5/R819
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